NEUROCRINE BIOSCIENCES INC Share-based Payment Arrangement, Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Share-based Payment Arrangement, Expense of $217.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for the quarter ending 2018-12-31 was $13.30M, a 1.13% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for the quarter ending 2018-09-30 was $13.07M, a 28.10% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for the quarter ending 2018-06-30 was $11.85M, a 19.83% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for the quarter ending 2018-03-31 was $19.88M, a 121.47% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for fiscal 2025 was $217.90M, a 11.46% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for fiscal 2024 was $195.50M, a 0.62% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for fiscal 2023 was $194.30M, a 12.25% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC share-based payment arrangement, expense for fiscal 2022 was $173.10M, a 28.99% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $217.90M 10-K · filed 2026-02-11 | |||||||
| 2024-12-31 | $195.50M 10-K · filed 2026-02-11 | |||||||
| 2023-12-31 | $194.30M 10-K · filed 2026-02-11 | |||||||
| 2022-12-31 | $173.10M 10-K · filed 2025-02-10 | |||||||
| 2021-12-31 | $134.20M 10-K · filed 2024-02-09 | |||||||
| 2020-12-31 | $100.00M 10-K · filed 2023-02-09 | |||||||
| 2019-12-31 | $75.30M 10-K · filed 2022-02-11 | $75.26M 10-K · filed 2020-02-07 | ||||||
| 2018-12-31 | $13.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $26.37M derived: sum of 2 quarters · filed 2021-02-05 | $38.22M derived: sum of 3 quarters · filed 2021-02-05 | $58.10M 10-K · filed 2021-02-05 | $58.07M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $13.07M 10-Q · filed 2018-11-05 | $24.92M derived: sum of 2 quarters · filed 2018-11-05 | $44.80M 10-Q · filed 2018-11-05 | $58.25M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | $11.85M 10-Q · filed 2018-07-31 | $31.73M 10-Q · filed 2018-07-31 | $45.18M derived: sum of 3 quarters · filed 2020-02-07 | $55.38M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | $19.88M 10-Q · filed 2018-04-30 | $33.33M derived: sum of 2 quarters · filed 2020-02-07 | $43.53M derived: sum of 3 quarters · filed 2020-02-07 | $53.42M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $13.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $23.66M derived: sum of 2 quarters · filed 2020-02-07 | $33.55M derived: sum of 3 quarters · filed 2020-02-07 | $42.52M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $10.20M 10-Q · filed 2018-11-05 | $10.20M 10-Q · filed 2017-11-01 | $20.09M derived: sum of 2 quarters · filed 2018-11-05 | $29.07M 10-Q · filed 2018-11-05 | $29.10M 10-Q · filed 2017-11-01 | $37.03M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-06-30 | $9.89M 10-Q · filed 2018-07-31 | $9.90M 10-Q · filed 2017-08-03 | $18.87M 10-Q · filed 2018-07-31 | $18.90M 10-Q · filed 2017-08-03 | $26.83M derived: sum of 3 quarters · filed 2019-02-08 | $33.13M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-03-31 | $8.98M 10-Q · filed 2018-04-30 | $9.00M 10-Q · filed 2017-05-09 | $16.94M derived: sum of 2 quarters · filed 2019-02-08 | $23.24M derived: sum of 3 quarters · filed 2019-02-08 | $30.54M derived: sum of 4 quarters · filed 2019-02-08 | |||
| 2016-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $14.26M derived: sum of 2 quarters · filed 2019-02-08 | $21.56M derived: sum of 3 quarters · filed 2019-02-08 | $28.46M 10-K · filed 2019-02-08 | ||||
| 2016-09-30 | $6.30M 10-Q · filed 2017-11-01 | $13.60M derived: sum of 2 quarters · filed 2017-11-01 | $20.50M 10-Q · filed 2017-11-01 | $26.69M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | $7.30M 10-Q · filed 2017-08-03 | $14.20M 10-Q · filed 2017-08-03 | $20.39M derived: sum of 3 quarters · filed 2018-02-13 | $34.29M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | $6.90M 10-Q · filed 2017-05-09 | $13.09M derived: sum of 2 quarters · filed 2018-02-13 | $26.99M derived: sum of 3 quarters · filed 2018-02-13 | $31.69M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $20.09M derived: sum of 2 quarters · filed 2018-02-13 | $24.79M derived: sum of 3 quarters · filed 2018-02-13 | $28.39M 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | $13.90M 10-Q · filed 2016-11-02 | $18.60M derived: sum of 2 quarters · filed 2016-11-02 | $22.20M 10-Q · filed 2016-11-02 | $24.68M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-06-30 | $4.70M 10-Q · filed 2016-08-03 | $8.30M 10-Q · filed 2016-08-03 | $10.78M derived: sum of 3 quarters · filed 2017-02-14 | $13.48M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-03-31 | $3.60M 10-Q · filed 2016-05-05 | $6.08M derived: sum of 2 quarters · filed 2017-02-14 | $8.78M derived: sum of 3 quarters · filed 2017-02-14 | $11.68M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2014-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $5.18M derived: sum of 2 quarters · filed 2017-02-14 | $8.08M derived: sum of 3 quarters · filed 2017-02-14 | $10.38M 10-K · filed 2017-02-14 | ||||
| 2014-09-30 | $2.70M 10-Q · filed 2015-10-29 | $5.60M derived: sum of 2 quarters · filed 2015-10-29 | $7.90M 10-Q · filed 2015-10-29 | $9.72M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $2.90M 10-Q · filed 2015-07-29 | $5.30M 10-Q · filed 2015-07-29 | $7.02M derived: sum of 3 quarters · filed 2016-02-11 | $8.72M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $2.40M 10-Q · filed 2015-04-30 | $4.12M derived: sum of 2 quarters · filed 2016-02-11 | $5.82M derived: sum of 3 quarters · filed 2016-02-11 | $7.52M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $3.42M derived: sum of 2 quarters · filed 2016-02-11 | $5.12M derived: sum of 3 quarters · filed 2016-02-11 | $6.82M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $1.70M 10-Q · filed 2014-11-04 | $3.40M derived: sum of 2 quarters · filed 2014-11-04 | $5.10M 10-Q · filed 2014-11-04 | $6.38M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-06-30 | $1.70M 10-Q · filed 2014-08-06 | $3.40M 10-Q · filed 2014-08-06 | $4.68M derived: sum of 3 quarters · filed 2015-02-09 | $6.08M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-03-31 | $1.70M 10-Q · filed 2014-05-01 | $2.98M derived: sum of 2 quarters · filed 2015-02-09 | $4.38M derived: sum of 3 quarters · filed 2015-02-09 | $5.78M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2012-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $2.68M derived: sum of 2 quarters · filed 2015-02-09 | $4.08M derived: sum of 3 quarters · filed 2015-02-09 | $5.48M 10-K · filed 2015-02-09 | ||||
| 2012-09-30 | $1.40M 10-Q · filed 2013-10-29 | $2.80M derived: sum of 2 quarters · filed 2013-10-29 | $4.20M 10-Q · filed 2013-10-29 | $5.12M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | $1.40M 10-Q · filed 2013-07-26 | $2.80M 10-Q · filed 2013-07-26 | $3.72M derived: sum of 3 quarters · filed 2014-02-11 | $4.62M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | $1.40M 10-Q · filed 2013-05-02 | $2.32M derived: sum of 2 quarters · filed 2014-02-11 | $3.22M derived: sum of 3 quarters · filed 2014-02-11 | $3.62M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $918.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $1.82M derived: sum of 2 quarters · filed 2014-02-11 | $2.22M derived: sum of 3 quarters · filed 2014-02-11 | $2.92M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $900.00K 10-Q · filed 2012-10-31 | $1.30M derived: sum of 2 quarters · filed 2012-10-31 | $2.00M 10-Q · filed 2012-10-31 | |||||
| 2011-06-30 | $400.00K 10-Q · filed 2012-07-31 | $1.10M 10-Q · filed 2012-07-31 | ||||||
| 2010-12-31 | $3.13M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |